Trials / Completed
CompletedNCT00401596
A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)
A Multicenter, Randomized, Controlled, Open-Label Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Subjects Already Treated With Other Therapies (ALTO)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,899 (planned)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 6 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This was a multicenter, open label, randomized, controlled, safety trial in subjects aged 6-75 years with a diagnosis of moderate to severe, persistent asthma. A total of 1899 subjects were randomized (2:1) to either the active treatment group or the control group. Upon successful completion of the screening period (\~2 weeks), each subject entered the 24 week study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xolair (omalizumab) |
Timeline
- Start date
- 2000-07-01
- Completion
- 2002-07-01
- First posted
- 2006-11-20
- Last updated
- 2014-03-19
Source: ClinicalTrials.gov record NCT00401596. Inclusion in this directory is not an endorsement.